Volume 3, Number 1—March 1997
Fluoroquinolone Resistance in Neisseria gonorrhoeae
||Zone Inhibition Diametersc
nearest whole mm
||Equivalent MICc (mg/ml)
|Ciprofloxacin, 250 mg||Cip, 1||≤24||≥0.03||8|
|Ciprofloxacin, 500 mg||Cip, 5||≤29||30-35||≥36||≥1.0||0.13-0.5||≤0.06||18|
|Ofloxacin, 400 mg||Ofx, 5||≤24||25-30||≥31||≥2.0||0.5-1.0||≤0.25||18|
|Enoxacin, 400 mg||Enx, 10||≤31||≥32||≥1.0||0.5||≤0.25||18|
|Lomefloxacin, 400 mg||Lom, 10||≤26||27-35||≥36||≥2.0||0.25-1.0||≤0.125||18|
|Norfloxacin, 800 mg||Nor, 5||≤32||33-35||≥36||≥1.0||0.5||≤0.25||18|
aThese criteria have not been recommended by the National Committee for Clinical Laboratory Standards (NCCLS); they are provided to guide interpretation of susceptibilities until the NCCLS establishes criteria.
bAbbreviations: MIC, minimal inhibitory concentration (µg/ml); R, resistant; I, intermediate resistance; S, susceptible; Cip, ciprofloxacin; Ofx, ofoxacin; Enx, enoxacin; Lom, lomefloxacin; Nor, norfloxacin.
cWith the exception of norfloxacin, criteria for the susceptible categories are those designated by the NCCLS (16,17); criteria for the interpretation of the susceptible category for norfloxacin were proposed by CDC (18).
- Page created: December 21, 2010
- Page last updated: December 21, 2010
- Page last reviewed: December 21, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)